Karyopharm Therapeutics Inc. Q4 2022 Earnings Call Transcript

KPTI Stock  USD 0.72  0.01  1.37%   
Under 61% of Karyopharm Therapeutics' investor base is looking to short. The analysis of the overall investor sentiment regarding Karyopharm Therapeutics suggests that many traders are alarmed. Karyopharm Therapeutics' investing sentiment shows overall attitude of investors towards Karyopharm Therapeutics.
  
Karyopharm Therapeutics Inc. Q4 2022 Earnings Call Transcript February 15, 2023 Operator Good day. My name is Andrea, and I will be your conference operator today. At this time, I would like to welcome everyone to the Karyopharm Therapeutics Fourth Quarter and Full Year 2022 Financial Results Conference Call. . Please be advised that

Read at finance.yahoo.com
Yahoo News
  

Karyopharm Therapeutics Fundamental Analysis

We analyze Karyopharm Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Karyopharm Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Karyopharm Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Current Liabilities

Current Liabilities Comparative Analysis

Karyopharm Therapeutics is currently under evaluation in current liabilities category among its peers. Current Liabilities is the company's short term debt. This usually includes obligations that are due within the next 12 months or within one fiscal year. Current liabilities are very important in analyzing a company's financial health as it requires the company to convert some of its current assets into cash.

Karyopharm Therapeutics Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Karyopharm Therapeutics stock to make a market-neutral strategy. Peer analysis of Karyopharm Therapeutics could also be used in its relative valuation, which is a method of valuing Karyopharm Therapeutics by comparing valuation metrics with similar companies.

Peers

Karyopharm Therapeutics Related Equities

GOSSGossamer Bio   28.17   
0%
100.0%
ASMBAssembly Biosciences   1.86   
0%
6.0%
PMVPPmv Pharmaceuticals   0.64   
0%
2.0%
ABOSAcumen Pharmaceuticals   0.46   
0%
1.0%
NUVBNuvation Bio   1.11   
3.0%
0%
NVCTNuvectis Pharma   1.49   
5.0%
0%
KRONKronos Bio   1.96   
6.0%
0%
BLUEBluebird Bio   2.56   
9.0%
0%
MREOMereo BioPharma   3.12   
11.0%
0%
REPLReplimune   3.32   
11.0%
0%
HOOKHookipa Pharma   3.60   
12.0%
0%
LYRALyra Therapeutics   4.76   
16.0%
0%
CTMXCytomX Therapeutics   5.08   
18.0%
0%
GBIOGeneration Bio   6.30   
22.0%
0%
RLYBRallybio Corp   6.67   
23.0%
0%
GLUEMonte Rosa   8.46   
30.0%
0%
AGIOAgios Pharm   11.99   
42.0%
0%
MRSNMersana Therapeutics   14.18   
50.0%
0%
XFORX4 Pharmaceuticals   21.05   
74.0%
0%

Complementary Tools for Karyopharm Stock analysis

When running Karyopharm Therapeutics' price analysis, check to measure Karyopharm Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Karyopharm Therapeutics is operating at the current time. Most of Karyopharm Therapeutics' value examination focuses on studying past and present price action to predict the probability of Karyopharm Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Karyopharm Therapeutics' price. Additionally, you may evaluate how the addition of Karyopharm Therapeutics to your portfolios can decrease your overall portfolio volatility.
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
FinTech Suite
Use AI to screen and filter profitable investment opportunities
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA